How Biotech Companies Can Select a Reliable Preclinical CRO: Key Factors That Truly Matter

For biotechnology companies, drug development is a race against time, capital, and scientific uncertainty. Outsourcing critical preclinical activities-such as pharmacology, toxicology, and translational efficacy studies-to a Contract Research Organization (CRO) is an established strategy to accelerate progress while mitigating risk.

However, choosing the wrong CRO can lead to unreliable data, project delays, or even downstream clinical failures-costly setbacks that no Biotech can afford.

So, how can Biotech teams identify a high-quality, trustworthy preclinical CRO among the many competing providers?
The answer lies in evaluating several fundamental dimensions. These criteria act not only as a "risk-avoidance checklist," but also as a practical roadmap for identifying an ideal long-term scientific partner.

The translational relevance of preclinical research is a major determinant of clinical success. Many CROs advertise "advanced animal models," but the true differentiation lies in whether their models:

• faithfully reproduce human disease physiology,
• exhibit consistent and reproducible phenotypes, and
• have been thoroughly validated with multidimensional endpoints.

Common Pitfall:

Avoid CROs that rely solely on traditional rodent models or maintain a narrow, outdated model library. Rodent-only data often lack predictive power for complex human diseases and may lead to inaccurate assessments of therapeutic efficacy.

Key Evaluation Criteria:

Look for CROs with deep expertise in nonhuman primate (NHP) models.
NHPs share high genetic, physiological, and pathological similarity with humans, making them essential for generating clinically predictive data, especially in areas such as CNS disorders, immunology, respiratory diseases, metabolic disorders, and ophthalmology.

Prisys Biotech's Strength:

As a leading CRO dedicated to NHP translational sciences, Prisys Biotech has established one of the most comprehensive NHP disease model platforms globally.

• Over 40 validated NHP disease models, covering respiratory, metabolic, immuno-inflammatory (e.g., rheumatoid arthritis), CNS, ophthalmology, and other therapeutic areas
• 57 technology patents and IP assets related to NHP modeling and translational research
  • Rigorous multi-parameter validation, including:
  • disease incidence
  • behavioral and clinical scoring
  • imaging readouts (MRI, PET, CT)
  • biomarkers such as CRP, cytokines, metabolic indicators

This systematic approach ensures stability, reproducibility, and regulatory readiness of data-providing strong support for IND submissions.

Large-animal studies-especially NHP research-require industrial-grade infrastructure, strict biosecurity, and advanced imaging and monitoring equipment. Facility quality directly determines:

• the types of studies that can be executed,
• the precision of measurements, and
• overall study reproducibility and compliance with global standards.

Accreditations serve as authoritative, third-party validation of a CRO's scientific competence, quality control practices, and ethical standards. Without globally recognized certifications, the data generated may face obstacles during multinational regulatory submissions and global clinical trial applications.

Common Pitfall:

Overlooking a CRO's international accreditations-such as AAALAC or ISO certifications.
This can lead to studies that fail to meet global regulatory expectations for ethics, animal welfare, and data quality.

Key Evaluation Criteria:

Prioritize CROs that have obtained full AAALAC International accreditation, the gold standard for animal care and use worldwide.
In addition, verify the presence of:

• valid and compliant Animal Use Licenses,
• a robust Institutional Animal Care and Use Committee (IACUC) system,
• ISO 9001–based quality management systems, and
• appropriate biosafety-level infrastructure (e.g., BSL-2).

Prisys Biotech's Accreditation Strengths:

Prisys Biotech has achieved full AAALAC International accreditation, maintains all legally required animal use licenses, and operates under a stringent IACUC review framework.
Our facilities meet BSL-2 standards, and our quality management system adheres to ISO 9001 principles.

These internationally recognized certifications ensure that our research services meet the highest global standards for ethics, quality, reproducibility, and data integrity-providing a solid foundation for IND-enabling studies and global regulatory submissions.

Preclinical research relies heavily on the scientific judgment, technical proficiency, and accumulated project experience of the research team.

An experienced scientific team understands the nuances of disease biology, can design robust and efficient study plans, and is capable of troubleshooting complex issues throughout the project lifecycle.

Common Pitfall:

• Being persuaded solely by sales presentations while neglecting to evaluate the actual scientific team's qualifications, prior project track record, and disease-area expertise.
• Teams lacking experience may struggle to manage high-complexity studies or interpret ambiguous results.

Key Evaluation Criteria:

Examine:

• the background and seniority of core scientific personnel,
• average years of industry experience,
• specialized expertise in relevant therapeutic areas (e.g., immunology, CNS, inflammation), and
• successful collaborations with leading domestic and multinational pharmaceutical companies.

Prisys Biotech's Scientific Team Strengths:

Prisys Biotech brings together an interdisciplinary team of returnee scientists, veteran medical specialists, veterinarians, and highly trained technical staff.
Our Founder and Chief Scientific Officer previously served as Senior Research Director, where he successfully advanced programs in antithrombotic, antiviral, and other therapeutic areas into clinical development. This cross-functional R&D experience directly enhances our ability to support complex translational programs.

The broader scientific team at Prisys Biotech averages over 15 years of hands-on experience in NHP research.
We provide comprehensive support throughout the entire outsourcing workflow-from early consultation and study design to data interpretation and regulatory-ready reporting.

1. Why are NHP models critical for certain therapeutic areas?

NHPs share high homology with humans in immune, metabolic, neurological, and respiratory systems. This makes them indispensable for evaluating biologics, gene therapies, CNS therapeutics, and other modalities requiring high translational fidelity.

2. How can I determine whether a CRO's disease models are truly validated?

Ask for:

• published data or validation reports
• biomarker and imaging evidence
• reproducibility metrics
• historical control datasets
• regulatory submission experience (e.g., IND-enabling packages)

3. What infrastructure should a high-quality NHP CRO possess?

Industrial-scale animal facilities, GLP/AAALAC-compliant operations, advanced imaging systems (MRI/PET/CT), telemetric monitoring, BSL-2/3 capabilities, and experienced veterinary and pathology teams.

4. Does working with an NHP-focused CRO extend timelines or increase cost?

Not necessarily. High-fidelity models reduce downstream development failures, saving time and investment by improving translational accuracy from preclinical to clinical stages.

5. What differentiates Prisys Biotech from traditional preclinical CROs?

Prisys combines:

• specialized NHP expertise,
• validated models across 40+ diseases,
• advanced imaging and biomarker platforms, and
• robust experience supporting global IND submissions.

This enables scientifically rigorous, clinically relevant data generation for complex therapeutic programs.